Home | Welcome to Contract Pharma   
Last Updated Thursday, October 30 2014
Print

Financial Report: Lilly



Published July 24, 2014
Lilly
 
2Q Revenues: $4.9 billion (-17%)

2Q Earnings: $733.5 million (-39%)

YTD Revenues: $9.6 billion (-17%)

YTD Earnings: $1.5 billion (-47%)

Comments: Results were impacted by the loss of U.S. patent exclusivity for Cymbalta, down 73% in the quarter to $401.3 billion, and Evista, down 61% to $108.3 million. Alimta sales were up 6% to $669.4 million. Humalog sales were up 11% to $628.6 million. Cialis sales were up 7% to $567.8 million. Lilly launched Cyramza in the quarter for gastric cancer or gastroesophageal junction (GEJ).


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On